Christina Marie Dieli-Conwright, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Resistance Training | 17 | 2024 | 198 | 8.450 |
Why?
|
Exercise | 33 | 2025 | 5955 | 3.040 |
Why?
|
Exercise Therapy | 14 | 2025 | 939 | 2.910 |
Why?
|
Breast Neoplasms | 30 | 2023 | 21206 | 2.580 |
Why?
|
Anthracyclines | 7 | 2022 | 286 | 2.180 |
Why?
|
Muscle Strength | 8 | 2024 | 640 | 1.850 |
Why?
|
Postmenopause | 11 | 2024 | 2518 | 1.760 |
Why?
|
Body Composition | 11 | 2023 | 2462 | 1.470 |
Why?
|
Sarcopenia | 3 | 2018 | 378 | 1.270 |
Why?
|
Muscle, Skeletal | 11 | 2024 | 4978 | 1.200 |
Why?
|
Physical Fitness | 9 | 2023 | 744 | 1.180 |
Why?
|
Androgen Antagonists | 4 | 2021 | 1412 | 1.000 |
Why?
|
Neoplasms | 13 | 2025 | 22365 | 0.930 |
Why?
|
Obesity | 16 | 2023 | 13091 | 0.910 |
Why?
|
Survivors | 6 | 2023 | 2381 | 0.840 |
Why?
|
Biliary Tract Neoplasms | 1 | 2023 | 187 | 0.770 |
Why?
|
Oxygen Consumption | 3 | 2020 | 1880 | 0.730 |
Why?
|
Nuclear Receptor Coactivator 1 | 2 | 2010 | 42 | 0.680 |
Why?
|
Nuclear Receptor Co-Repressor 2 | 2 | 2010 | 33 | 0.670 |
Why?
|
Estrogen Replacement Therapy | 3 | 2012 | 1209 | 0.660 |
Why?
|
Pilot Projects | 11 | 2024 | 8740 | 0.640 |
Why?
|
Matrix Metalloproteinases | 1 | 2020 | 393 | 0.570 |
Why?
|
Electric Impedance | 3 | 2018 | 795 | 0.520 |
Why?
|
Overweight | 4 | 2023 | 2448 | 0.520 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2023 | 957 | 0.510 |
Why?
|
Absorptiometry, Photon | 4 | 2018 | 1758 | 0.510 |
Why?
|
Cardiovascular Diseases | 5 | 2023 | 15660 | 0.510 |
Why?
|
Mitochondrial Proteins | 1 | 2021 | 979 | 0.500 |
Why?
|
Motor Activity | 5 | 2014 | 2711 | 0.490 |
Why?
|
Fasting | 1 | 2021 | 1609 | 0.490 |
Why?
|
Hormone Replacement Therapy | 2 | 2011 | 757 | 0.470 |
Why?
|
Central Nervous System Neoplasms | 1 | 2023 | 928 | 0.470 |
Why?
|
Pituitary Neoplasms | 1 | 2023 | 1322 | 0.460 |
Why?
|
Subcutaneous Fat | 1 | 2017 | 404 | 0.460 |
Why?
|
Myostatin | 2 | 2012 | 129 | 0.440 |
Why?
|
Quality of Life | 12 | 2025 | 13489 | 0.430 |
Why?
|
Recreation | 1 | 2013 | 124 | 0.410 |
Why?
|
Prostatic Neoplasms | 4 | 2021 | 11101 | 0.410 |
Why?
|
Humans | 74 | 2025 | 767991 | 0.400 |
Why?
|
Dietary Proteins | 1 | 2017 | 960 | 0.390 |
Why?
|
Female | 50 | 2024 | 397113 | 0.380 |
Why?
|
Health Status Disparities | 1 | 2023 | 1885 | 0.380 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2019 | 1536 | 0.350 |
Why?
|
Insulin Resistance | 2 | 2022 | 3986 | 0.350 |
Why?
|
Middle Aged | 32 | 2024 | 223422 | 0.350 |
Why?
|
Endometrial Neoplasms | 2 | 2023 | 1382 | 0.330 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 11873 | 0.330 |
Why?
|
Estrogens | 3 | 2012 | 1536 | 0.330 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2009 | 131 | 0.310 |
Why?
|
Muscle Cells | 1 | 2009 | 195 | 0.300 |
Why?
|
RNA, Messenger | 6 | 2016 | 12797 | 0.300 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2016 | 1942 | 0.300 |
Why?
|
Antineoplastic Agents | 4 | 2025 | 13658 | 0.280 |
Why?
|
Fatigue | 5 | 2025 | 1557 | 0.280 |
Why?
|
Endothelium, Vascular | 1 | 2019 | 4427 | 0.280 |
Why?
|
Multiple Myeloma | 1 | 2024 | 5196 | 0.270 |
Why?
|
Physical Exertion | 1 | 2009 | 668 | 0.270 |
Why?
|
Neoadjuvant Therapy | 3 | 2017 | 2902 | 0.260 |
Why?
|
Gene Expression | 4 | 2016 | 7597 | 0.260 |
Why?
|
Monitoring, Physiologic | 2 | 2014 | 1798 | 0.250 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2024 | 10396 | 0.250 |
Why?
|
Adult | 26 | 2024 | 223583 | 0.240 |
Why?
|
Receptors, Estrogen | 2 | 2010 | 2253 | 0.240 |
Why?
|
Muscle Proteins | 1 | 2009 | 1165 | 0.220 |
Why?
|
Neoplasm Staging | 6 | 2019 | 11221 | 0.220 |
Why?
|
Medical Oncology | 4 | 2023 | 2341 | 0.210 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2021 | 9412 | 0.210 |
Why?
|
California | 3 | 2017 | 1438 | 0.210 |
Why?
|
Colorectal Neoplasms | 1 | 2022 | 6973 | 0.200 |
Why?
|
Triglycerides | 2 | 2022 | 2463 | 0.190 |
Why?
|
Estradiol | 1 | 2009 | 1951 | 0.190 |
Why?
|
Aged | 19 | 2024 | 171446 | 0.190 |
Why?
|
Exercise Test | 1 | 2009 | 2186 | 0.190 |
Why?
|
Carcinoembryonic Antigen | 1 | 2022 | 338 | 0.180 |
Why?
|
Hematologic Neoplasms | 2 | 2023 | 1907 | 0.180 |
Why?
|
Energy Metabolism | 4 | 2023 | 2908 | 0.180 |
Why?
|
Matrix Metalloproteinase 10 | 1 | 2020 | 11 | 0.180 |
Why?
|
Blood Pressure | 1 | 2016 | 8540 | 0.170 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 1560 | 0.170 |
Why?
|
Follistatin | 2 | 2012 | 138 | 0.170 |
Why?
|
Anthropometry | 3 | 2010 | 1346 | 0.170 |
Why?
|
Ki-67 Antigen | 1 | 2022 | 630 | 0.170 |
Why?
|
Tissue Inhibitor of Metalloproteinase-2 | 1 | 2020 | 71 | 0.170 |
Why?
|
Matrix Metalloproteinase 7 | 1 | 2020 | 60 | 0.170 |
Why?
|
Matrix Metalloproteinase 1 | 1 | 2020 | 147 | 0.170 |
Why?
|
Tissue Inhibitor of Metalloproteinase-1 | 1 | 2020 | 149 | 0.170 |
Why?
|
Risk Factors | 7 | 2024 | 74936 | 0.170 |
Why?
|
Inflammation | 2 | 2017 | 10871 | 0.170 |
Why?
|
Transplantation, Autologous | 1 | 2024 | 2120 | 0.170 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2023 | 388 | 0.160 |
Why?
|
Treatment Outcome | 9 | 2025 | 65364 | 0.160 |
Why?
|
Abdominal Fat | 1 | 2020 | 220 | 0.150 |
Why?
|
Male | 20 | 2024 | 364641 | 0.150 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2020 | 461 | 0.150 |
Why?
|
Daunorubicin | 1 | 2017 | 157 | 0.140 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2020 | 633 | 0.140 |
Why?
|
Blood Glucose Self-Monitoring | 1 | 2020 | 475 | 0.140 |
Why?
|
Eating | 1 | 2023 | 1542 | 0.130 |
Why?
|
Biopsy | 3 | 2017 | 6786 | 0.130 |
Why?
|
Women's Health | 2 | 2022 | 2082 | 0.120 |
Why?
|
Cognition | 2 | 2024 | 7072 | 0.120 |
Why?
|
Regional Blood Flow | 1 | 2018 | 1500 | 0.120 |
Why?
|
Proportional Hazards Models | 3 | 2022 | 12536 | 0.120 |
Why?
|
Muscle Fatigue | 1 | 2015 | 96 | 0.120 |
Why?
|
Gene Expression Regulation | 2 | 2009 | 11930 | 0.120 |
Why?
|
Glucose | 2 | 2024 | 4351 | 0.110 |
Why?
|
Body Mass Index | 3 | 2023 | 13053 | 0.110 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 4576 | 0.110 |
Why?
|
Calorimetry, Indirect | 1 | 2014 | 177 | 0.110 |
Why?
|
Quadriceps Muscle | 1 | 2015 | 157 | 0.110 |
Why?
|
Cause of Death | 1 | 2024 | 3720 | 0.110 |
Why?
|
Minority Groups | 1 | 2021 | 1217 | 0.110 |
Why?
|
Cholesterol | 1 | 2022 | 2914 | 0.110 |
Why?
|
Leukocytes, Mononuclear | 1 | 2020 | 1854 | 0.110 |
Why?
|
Androgens | 1 | 2021 | 1281 | 0.110 |
Why?
|
Faculty | 2 | 2013 | 383 | 0.110 |
Why?
|
Range of Motion, Articular | 1 | 2019 | 1597 | 0.100 |
Why?
|
Shoulder Joint | 1 | 2019 | 745 | 0.100 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2017 | 4351 | 0.100 |
Why?
|
Prostate-Specific Antigen | 1 | 2022 | 2463 | 0.100 |
Why?
|
Waist Circumference | 1 | 2016 | 935 | 0.100 |
Why?
|
Follistatin-Related Proteins | 1 | 2012 | 48 | 0.100 |
Why?
|
Premenopause | 1 | 2016 | 1039 | 0.100 |
Why?
|
Prospective Studies | 4 | 2024 | 54924 | 0.100 |
Why?
|
Mastectomy | 1 | 2020 | 1861 | 0.100 |
Why?
|
Adiponectin | 1 | 2017 | 1117 | 0.100 |
Why?
|
Activin Receptors, Type II | 1 | 2012 | 122 | 0.090 |
Why?
|
Feasibility Studies | 2 | 2020 | 5314 | 0.090 |
Why?
|
Diet | 4 | 2023 | 8087 | 0.090 |
Why?
|
Home Care Services | 1 | 2018 | 659 | 0.090 |
Why?
|
Protein Isoforms | 1 | 2016 | 1715 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2017 | 3553 | 0.090 |
Why?
|
Disease Management | 1 | 2021 | 2533 | 0.090 |
Why?
|
Activities of Daily Living | 1 | 2019 | 2429 | 0.090 |
Why?
|
Athletic Performance | 1 | 2011 | 113 | 0.090 |
Why?
|
Actigraphy | 1 | 2014 | 527 | 0.090 |
Why?
|
Cholesterol, HDL | 1 | 2016 | 1820 | 0.080 |
Why?
|
Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2009 | 79 | 0.080 |
Why?
|
Young Adult | 7 | 2023 | 60048 | 0.080 |
Why?
|
Follow-Up Studies | 2 | 2024 | 39345 | 0.080 |
Why?
|
Progestins | 1 | 2011 | 302 | 0.080 |
Why?
|
Stress, Psychological | 1 | 2024 | 4530 | 0.080 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2021 | 2538 | 0.080 |
Why?
|
Immunity, Innate | 1 | 2020 | 3079 | 0.080 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2009 | 412 | 0.070 |
Why?
|
Sleep | 2 | 2021 | 4817 | 0.070 |
Why?
|
Progesterone | 1 | 2012 | 752 | 0.070 |
Why?
|
Interleukin-6 | 1 | 2017 | 3228 | 0.070 |
Why?
|
Blood Chemical Analysis | 1 | 2009 | 435 | 0.070 |
Why?
|
Creatine Kinase | 1 | 2009 | 684 | 0.070 |
Why?
|
Child | 8 | 2024 | 80906 | 0.070 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 8535 | 0.070 |
Why?
|
Blood Glucose | 2 | 2024 | 6429 | 0.070 |
Why?
|
Physical Endurance | 1 | 2009 | 369 | 0.070 |
Why?
|
Human Growth Hormone | 1 | 2011 | 651 | 0.070 |
Why?
|
Medication Adherence | 1 | 2018 | 2187 | 0.070 |
Why?
|
DNA, Complementary | 1 | 2009 | 1989 | 0.060 |
Why?
|
Adolescent | 9 | 2024 | 89155 | 0.060 |
Why?
|
Bone Density | 1 | 2018 | 3573 | 0.060 |
Why?
|
Lipids | 1 | 2016 | 3342 | 0.060 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2012 | 1656 | 0.060 |
Why?
|
Menopause | 1 | 2013 | 1656 | 0.060 |
Why?
|
Tamoxifen | 1 | 2009 | 966 | 0.060 |
Why?
|
Tumor Microenvironment | 1 | 2017 | 3948 | 0.060 |
Why?
|
Dietary Supplements | 1 | 2017 | 3445 | 0.060 |
Why?
|
C-Reactive Protein | 1 | 2016 | 3858 | 0.060 |
Why?
|
Clinical Trials as Topic | 1 | 2020 | 8052 | 0.060 |
Why?
|
Transcriptional Activation | 1 | 2010 | 1752 | 0.060 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2025 | 300 | 0.050 |
Why?
|
Macrophages | 1 | 2017 | 5799 | 0.050 |
Why?
|
Research Design | 1 | 2018 | 6211 | 0.050 |
Why?
|
Administrative Personnel | 1 | 2023 | 185 | 0.050 |
Why?
|
Pandemics | 1 | 2022 | 8748 | 0.050 |
Why?
|
Cross-Sectional Studies | 1 | 2023 | 26375 | 0.050 |
Why?
|
Breast | 1 | 2011 | 1976 | 0.050 |
Why?
|
Adipose Tissue | 2 | 2010 | 3329 | 0.050 |
Why?
|
Technology | 1 | 2023 | 296 | 0.040 |
Why?
|
Polymerase Chain Reaction | 1 | 2010 | 6071 | 0.040 |
Why?
|
Disease Progression | 1 | 2017 | 13665 | 0.040 |
Why?
|
Testosterone | 1 | 2011 | 2491 | 0.040 |
Why?
|
Geriatric Assessment | 2 | 2022 | 1422 | 0.040 |
Why?
|
Diet, Fat-Restricted | 1 | 2022 | 328 | 0.040 |
Why?
|
Cyclophosphamide | 2 | 2017 | 2227 | 0.040 |
Why?
|
United States | 3 | 2025 | 73027 | 0.040 |
Why?
|
RNA | 1 | 2009 | 2718 | 0.040 |
Why?
|
Prevalence | 1 | 2016 | 15867 | 0.040 |
Why?
|
Doxorubicin | 2 | 2017 | 2234 | 0.040 |
Why?
|
20-Hydroxysteroid Dehydrogenases | 1 | 2017 | 6 | 0.040 |
Why?
|
Hydroxysteroid Dehydrogenases | 1 | 2017 | 30 | 0.040 |
Why?
|
Aldehyde Reductase | 1 | 2017 | 70 | 0.040 |
Why?
|
Arteries | 1 | 2022 | 1127 | 0.040 |
Why?
|
Proteins | 1 | 2012 | 6009 | 0.040 |
Why?
|
Chemokine CCL3 | 1 | 2017 | 85 | 0.030 |
Why?
|
Chemokine CCL11 | 1 | 2017 | 128 | 0.030 |
Why?
|
Alcohol Oxidoreductases | 1 | 2017 | 164 | 0.030 |
Why?
|
Trail Making Test | 1 | 2017 | 57 | 0.030 |
Why?
|
Vegetables | 1 | 2022 | 1199 | 0.030 |
Why?
|
Nutritional Status | 1 | 2025 | 1628 | 0.030 |
Why?
|
Smoking | 1 | 2013 | 9089 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2021 | 1014 | 0.030 |
Why?
|
Ergometry | 1 | 2015 | 17 | 0.030 |
Why?
|
Energy Intake | 1 | 2023 | 2145 | 0.030 |
Why?
|
Prognosis | 1 | 2016 | 29979 | 0.030 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2017 | 299 | 0.030 |
Why?
|
Isometric Contraction | 1 | 2015 | 149 | 0.030 |
Why?
|
Fractals | 1 | 2015 | 127 | 0.030 |
Why?
|
Chemokine CCL2 | 1 | 2017 | 605 | 0.030 |
Why?
|
Interleukin-12 | 1 | 2017 | 577 | 0.030 |
Why?
|
Cytokines | 1 | 2009 | 7450 | 0.030 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2017 | 658 | 0.030 |
Why?
|
Aging | 1 | 2013 | 8744 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2011 | 22287 | 0.030 |
Why?
|
Intestinal Mucosa | 1 | 2023 | 3044 | 0.030 |
Why?
|
Lymphocytes | 1 | 2020 | 2614 | 0.030 |
Why?
|
Self Report | 2 | 2017 | 3773 | 0.030 |
Why?
|
Radiotherapy | 1 | 2019 | 1501 | 0.020 |
Why?
|
Adipocytes | 1 | 2017 | 1197 | 0.020 |
Why?
|
Caregivers | 1 | 2023 | 2302 | 0.020 |
Why?
|
Analysis of Variance | 2 | 2010 | 6228 | 0.020 |
Why?
|
Diffusion Tensor Imaging | 1 | 2021 | 2422 | 0.020 |
Why?
|
Menarche | 1 | 2013 | 538 | 0.020 |
Why?
|
Electric Stimulation | 1 | 2015 | 1740 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2020 | 5902 | 0.020 |
Why?
|
Electromyography | 1 | 2015 | 1399 | 0.020 |
Why?
|
Health Personnel | 1 | 2023 | 3385 | 0.020 |
Why?
|
Child Development | 1 | 2021 | 2330 | 0.020 |
Why?
|
Leisure Activities | 1 | 2010 | 310 | 0.020 |
Why?
|
Animals | 2 | 2022 | 169222 | 0.020 |
Why?
|
Plethysmography | 1 | 2008 | 172 | 0.020 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2015 | 1488 | 0.020 |
Why?
|
Thinness | 1 | 2011 | 482 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2023 | 9536 | 0.020 |
Why?
|
Linear Models | 1 | 2017 | 5884 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2019 | 3269 | 0.020 |
Why?
|
Pregnancy | 2 | 2021 | 30260 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2019 | 3237 | 0.010 |
Why?
|
Age Factors | 2 | 2013 | 18407 | 0.010 |
Why?
|
Neuropsychological Tests | 1 | 2017 | 7140 | 0.010 |
Why?
|
Reference Values | 1 | 2010 | 4938 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2017 | 5335 | 0.010 |
Why?
|
Reproducibility of Results | 2 | 2010 | 20218 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2017 | 17128 | 0.010 |
Why?
|
Health Surveys | 1 | 2010 | 4056 | 0.010 |
Why?
|
Aged, 80 and over | 3 | 2010 | 59598 | 0.010 |
Why?
|
Equipment Design | 1 | 2008 | 3522 | 0.010 |
Why?
|
Heart Rate | 1 | 2010 | 4215 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2011 | 12464 | 0.010 |
Why?
|
Depression | 1 | 2017 | 8231 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2010 | 7851 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2019 | 15831 | 0.010 |
Why?
|
Software | 1 | 2010 | 4478 | 0.010 |
Why?
|
Mice | 1 | 2022 | 82024 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2011 | 15442 | 0.010 |
Why?
|
Sex Factors | 1 | 2008 | 10627 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2008 | 14718 | 0.010 |
Why?
|
Cohort Studies | 1 | 2013 | 41749 | 0.010 |
Why?
|
Algorithms | 1 | 2010 | 14163 | 0.010 |
Why?
|